The global cell line development market is dominated by three major players, namely, American Type Culture Collection (ATCC) (U.S.), Lonza Group AG (U.S.), and Thermo Fisher Scientific, Inc. (U.S.). These players jointly account for approximately 72% of the total cell line development market.
ATCC accounted for the largest share of the cell line development market. Its cell lines, culture reagents, and cell line authentication and characterization services are widely used across the end-user market, thus positioning it as a market leader. The company strengthened its position in the market through partnerships and agreements. For instance, in June 2012, ATCC entered into an agreement with Life Technologies Corporation (U.S.), giving ATCC exclusive rights to sell products based on the green fluorescent protein (GFP) technology to non-commercial customers, distributors, and government customers operating in the field of research.
Lonza Group offers a wide range of products for cell line development including specialty media, classical media, mycoplasma detection & removal, and reagents. In addition, it offers cell products like CHO, hybridomas, various mouse myelomas, and human cell lines used for production of monoclonal antibodies and recombinant proteins. The company’s primary focus is on forming partnerships with companies through agreements, to widen their customer base. For instance, in March 2014, the company, along with BioWa, Inc., signed an agreement with arGEN-X BV (Netherlands) for the commercial use of Lonza’s POTELLIGENT CHOK1SV cell line. This agreement enabled arGEN-X BV to use cell lines for research, development, and production of multiple proprietary antibodies. In addition, in July 2013, the company signed an agreement with Pfizer, Inc, which enabled Pfizer to use these POTELLIGENT CHOK1SV cell lines for the research and development of antibodies.
Various key growth strategies such as new product launches, agreements, partnerships and collaborations, expansions, and acquisitions were adopted by key players in the cell line development market to expand their global footprint and market share. For instance, in February 2014, Thermo Fisher Scientific acquired Life Technologies (U.S) for approximately $13.6 billion. This acquisition opened a new reporting segment called Life Sciences Solutions in Thermo Fisher’s business segments. In addition, in January 2014, GE Healthcare signed an agreement to acquire Thermo Fisher’s HyClone cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion. The acquisition will enable GE to expand its technology offerings for the discovery and manufacturing of new innovative medicines, vaccines and diagnostics in its growing Life Sciences business. Further, in April 2013, Sigma Life Science, the innovative biological products and services business unit of Sigma-Aldrich Corporation, and the European Collection of Cell Cultures (ECACC) entered into an agreement. As per the agreement, the collection of well-preserved, unique, and authenticated human and animal cell cultures and cell lines of ECACC will be distributed through Sigma.
Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Email: [email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE